M Rigo-Adrover1,2, S Saldaña-Ruíz1,2, K van Limpt3, K Knipping3,4, J Garssen3,4, J Knol3, A Franch1,2, M Castell1,2, F J Pérez-Cano5,6. 1. Department of Physiology, Faculty of Pharmacy, University of Barcelona, Av. Joan XXIII s/n, 08028, Barcelona, Spain. 2. Nutrition and Food Safety Research Institute (INSA), Barcelona, Spain. 3. Nutricia Research, Utrecht, The Netherlands. 4. Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands. 5. Department of Physiology, Faculty of Pharmacy, University of Barcelona, Av. Joan XXIII s/n, 08028, Barcelona, Spain. franciscoperez@ub.edu. 6. Nutrition and Food Safety Research Institute (INSA), Barcelona, Spain. franciscoperez@ub.edu.
Abstract
PURPOSE: Rotavirus (RV) is the leading cause of severe diarrhoea among infants and young children, and although more standardized studies are needed, there is evidence that probiotics can help to fight against RV and other infectious and intestinal pathologies. On the other hand, the effects of prebiotics have not been properly addressed in the context of an RV infection. The aim of this study was to demonstrate a protective role for a specific scGOS/lcFOS 9:1 prebiotic mixture (PRE) separately, the probiotic Bifidobacterium breve M-16V (PRO) separately and the combination of the prebiotic mixture and the probiotic (synbiotic, SYN) in a suckling rat RV infection model. METHODS: The animals received the intervention from the 3rd to the 21st day of life by oral gavage. On day 7, RV was orally administered. Clinical parameters and immune response were evaluated. RESULTS: The intervention with the PRO reduced the incidence, severity and duration of the diarrhoea (p < 0.05). The PRE and SYN products improved clinical parameters as well, but a change in stool consistency induced by the PRE intervention hindered the observation of this effect. Both the PRE and the SYN, but not the PRO, significantly reduced viral shedding. All interventions modulated the specific antibody response in serum and intestinal washes at day 14 and 21 of life. CONCLUSIONS: A daily supplement of a scGOS/lcFOS 9:1 prebiotic mixture, Bifidobacterium breve M-16V or a combination of both is highly effective in modulating RV-induced diarrhoea in this preclinical model.
PURPOSE: Rotavirus (RV) is the leading cause of severe diarrhoea among infants and young children, and although more standardized studies are needed, there is evidence that probiotics can help to fight against RV and other infectious and intestinal pathologies. On the other hand, the effects of prebiotics have not been properly addressed in the context of an RV infection. The aim of this study was to demonstrate a protective role for a specific scGOS/lcFOS 9:1 prebiotic mixture (PRE) separately, the probiotic Bifidobacterium breve M-16V (PRO) separately and the combination of the prebiotic mixture and the probiotic (synbiotic, SYN) in a suckling rat RV infection model. METHODS: The animals received the intervention from the 3rd to the 21st day of life by oral gavage. On day 7, RV was orally administered. Clinical parameters and immune response were evaluated. RESULTS: The intervention with the PRO reduced the incidence, severity and duration of the diarrhoea (p < 0.05). The PRE and SYN products improved clinical parameters as well, but a change in stool consistency induced by the PRE intervention hindered the observation of this effect. Both the PRE and the SYN, but not the PRO, significantly reduced viral shedding. All interventions modulated the specific antibody response in serum and intestinal washes at day 14 and 21 of life. CONCLUSIONS: A daily supplement of a scGOS/lcFOS 9:1 prebiotic mixture, Bifidobacterium breve M-16V or a combination of both is highly effective in modulating RV-induced diarrhoea in this preclinical model.
Authors: L C Duffy; M A Zielezny; M Riepenhoff-Talty; D Dryja; S Sayahtaheri-Altaie; E Griffiths; D Ruffin; H Barrett; J Rossman; P L Ogra Journal: Pediatr Res Date: 1994-06 Impact factor: 3.756
Authors: Kristin Schmidt; Philip J Cowen; Catherine J Harmer; George Tzortzis; Steven Errington; Philip W J Burnet Journal: Psychopharmacology (Berl) Date: 2014-12-03 Impact factor: 4.530
Authors: Maria Del Mar Rigo-Adrover; Àngels Franch; Margarida Castell; Francisco José Pérez-Cano Journal: PLoS One Date: 2016-11-07 Impact factor: 3.240
Authors: Maria Del Mar Rigo-Adrover; Kees van Limpt; Karen Knipping; Johan Garssen; Jan Knol; Adele Costabile; Àngels Franch; Margarida Castell; Francisco José Pérez-Cano Journal: Front Immunol Date: 2018-06-11 Impact factor: 7.561
Authors: Andrew HyoungJin Kim; Michael P Hogarty; Vanessa C Harris; Megan T Baldridge Journal: Front Cell Infect Microbiol Date: 2021-01-08 Impact factor: 5.293